The high incidence of cardiovascular disease and colorectal cancer in the world's population means that these
two conditions may coexist in the same patient. In addition fluoropyrimidines, backbone for the treatment of colorectal
cancer in both early stage and advanced disease, have a well-characterized cardio-toxicity, which limits their use in
patients with heart disease and limits their reintroduction in those patients who have shown this toxicity. For the treatment
of this, increasing proportion of patients is now possible to consider fluoropyrimidines-free chemotherapy regimens that
are examined in this work, with the attempt to provide a possible treatment algorithm for various situations encountered in
Keywords: Cardiovascular disease, cardiotoxicity, colorectal cancer, fluoropirymidines.
Rights & PermissionsPrintExport